| Expression pattern: |
UP |
| Associated gene: |
QKI, ERK1/2, pERK1/2, DUSP6, DHX9 |
| Associated microRNA: |
- |
| Biological function: |
Promotes gastric cancer cell migration, invasion, EMT, metastasis, progression, and ERK inhibitor resistance; enhances biogenesis of oncogenic circRNAs. |
| Molecular mechanism: |
QKI promotes circPDIA4 biogenesis; circPDIA4 binds ERK1/2 and prevents DUSP6-mediated pERK dephosphorylation to activate MAPK/ERK signaling; circPDIA4 binds DHX9 as a decoy in the nucleus to facilitate biogenesis of oncogenic circRNAs. |
| Biological pathway or process: |
MAPK (promotes); ERK (promotes); migration (promotes); invasion (promotes); metastasis (promotes); EMT (promotes); drug resistance (promotes); other pathway/process (promotes) |
| Detected method: |
Q
|
| Validation methods: |
Back-Splice Junction PCR / divergent primers PCR; RNase R Treatment; Sanger Sequencing; RT-qPCR; Clinical Sample Validation; RNA Pull-Down; RIP (RNA Immunoprecipitation); Co-IP; IF (Immunofluorescence); Nuclear-Cytoplasmic Fractionation; RNA-seq; circRNA-seq; Transfection; MTT; Colony Formation Assay; Transwell Assay; Wound Healing Assay; In Vivo Animal Model; H&E Staining; IHC (Immunohistochemistry); Western Blot; Cohort Study; Survival Analysis; Bioinformatics Analysis |
| Clinical significance: |
High circPDIA4 expression is associated with shorter progression-free survival and overall survival in gastric cancer patients and may represent a therapeutic target. |
| Description: |
circPDIA4 is a human PDIA4-derived circRNA that is up-regulated in gastric cancer and predicts poor survival. It promotes migration, invasion, EMT, metastasis, and ERK inhibitor resistance by sustaining ERK1/2 phosphorylation and by acting as a DHX9 decoy to enhance oncogenic circRNA biogenesis. |
| Confidence score: |
0.8961 |